Ann: Phase II TACTI-002 trial recruitment successfully completed, page-6

Yes. Efti has already demonstrated that it can greatly increase the number of patients that will benefit from Keytruda in head and neck and small cell lung cancer with a fraction of the side effects of Keytruda and chemo.
Which means BIG dollars.
It is no accident that the FDA have fast tracked the head and neck trial and the lung cancer trial has expanded dramatically and recruited ahead of schedule. Tacti-003 has started enrolling and how quickly it recruits will give us a very good indication of our status. This is a company making trial and will be exciting to follow.

Can’t understand why the share price is slipping back but that’s how it goes. Should be a very interesting 2022.